Zealand Pharma A/S (NASDAQ: ZEAL) and Roche announced plans to advance petrelintide, an amylin analog, into Phase 3 trials for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE